Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1
NCT04770155 · University of Mississippi Medical Center · EARLY_PHASE1 · terminated · last registry update 2023-10-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Despite significant effort, we were unable to obtain the supply of drugs and supplements needed for the various arms of this Clinical Trial.” | – | Registry record, University of Mississippi Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE5A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-30Results posted on the registry: MediciNova, Ibudilast + Placebo (NCT04429555)
- 2024-10-15Results posted on the registry: University of Missouri-Columbia, Pentoxifylline + Placebo (NCT02592863)
- 2024-10-15Also stopped (terminated): University of Missouri-Columbia, Pentoxifylline + Placebo (NCT02592863)
- 2024-10-01Results posted on the registry: Philips Clinical & Medical Affairs Global, a drug against PDE5A (NCT04696354)
- 2024-09-25Also stopped (terminated): Iain Bressendorff, ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib (NCT05897372)
- 2024-09-24Results posted on the registry: MediciNova, ibudilast + Ibudilast (NCT02714036)
- 2024-09-23Results posted on the registry: Boston Medical Group, a drug against PDE5A (NCT03596047)
- 2024-09-04Phase 3 first posted: Aswan University Hospital, Botulinum toxin A + Tadalafil 5mg (NCT06583590)
- 2024-08-02Results posted on the registry: Shionogi, MT-1186 + Rosuvastatin (NCT04481789)
- 2024-07-26Phase 3 first posted: University of Alabama at Birmingham, Sildenafil 50 mg Oral Tablet + Placebo Oral Tablet (NCT06522854)
- 2024-07-25Phase 3 first posted: University Medical Centre Ljubljana, Tadalafil 5mg (NCT06520839)
- 2024-07-10Results posted on the registry: Montefiore Medical Center, Sildenafil + Placebo Oral Tablet (NCT03199612)
- 2024-07-08Phase 3 first posted: Tanta University, Vardenafil 5 Mg Oral Tablet (NCT06491108)
- 2024-06-20Phase 3 first posted: Al-Azhar University, Tadalafil (NCT06466369)
- 2024-05-20Phase 3 first posted: Ain Shams University, Dapagliflozin 10mg Tab + Pentoxifylline 400 MG (NCT06421870)
- 2024-05-20Phase 3 first posted: Tanta University, Pentoxifylline + Probiotic Formula (NCT06422000)
- 2024-05-16Also stopped (withdrawn): University of British Columbia, Sildenafil (NCT04122105)
- 2024-04-22Phase 3 first posted: University of Alabama at Birmingham, Sildenafil 50 mg Oral Tablet + Placebo Oral Tablet (NCT06377098)
- 2024-02-28Also stopped (terminated): Uniformed Services University of the Health Sciences, Sildenafil Citrate 50Mg Tab + Gadolinium contrast infusion (NCT04058132)
- 2024-02-20Also stopped (terminated): Nanjing First Hospital, Nanjing Medical University, Sildenafil (NCT02284737)
- 2024-01-11Also stopped (terminated): Baylor College of Medicine, Pentoxifylline (NCT01774487)
- 2023-11-13Results posted on the registry: Actelion, FDC macitentan/tadalafil + Macitentan 10 mg (NCT03904693)
- 2023-11-08Phase 3 first posted: University Hospital, Rouen, Sildenafil (NCT06123156)
- 2023-11-07Also stopped (terminated): Clear Creek Bio, Inc., Brequinar Sodium + Dipyridamole 75 MG (NCT05166876)
- 2023-10-12Results posted on the registry: Baylor College of Medicine, Pentoxifylline (NCT01774487)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision